Grifols disappoints investors

07/31/2014 4:42 PM

07/31/2014 4:44 PM

Grifols, a major producer of blood-plasma products and Johnston County’s largest employer, suffered the consequences of disappointing investors.

The Spainish company’s American depositary receipts, which are similar to common stock for companies based overseas, fell 13 percent to $36.67 on Thursday.

The Spain-based company posted a 23 percent jump in net profit to 224.8 million euros, or $301.2 million, for the first half of the year. But analysts had anticipated net profit of 243 million euros, according to Bloomberg News.

EBITDA – earnings before interest, taxes, depreciation, and amortization – also fell short of expectations.

Revenue for the first six months of the year of 1.61 billion euros, or $2.16 billion, was in line with analysts’ estimates.

Grifols established a presence in the Triangle when it acquire Talecris for $3.4 billion in 2010. Today Talecris has 1,650 employees in Clayton and 2,300 in North Carolina.

The company’s products made from blood plasma are administered to people with illnesses such as hemophilia and Alzheimer’s.

Join the Discussion

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere on the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Terms of Service